67. Polycystic kidney disease
186 clinical trials,   196 drugs   (DrugBank: 47 drugs),   35 drug target genes,   146 drug target pathways

Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000012865
2014/06/3001/03/2014Ursodeoxycholic acid for polycystic liver diseaseUrsodeoxycholic acid for polycystic liver disease - UDCA for PLD polycystic liver disease, polycystic kidney diseaseUDCA 600mg/day
standard treatment
Nephrology Center, Toranomon HospitalNULLRecruitingNot applicableNot applicableMale and Female100Not selectedJapan
2NCT02021110
(ClinicalTrials.gov)
December 201312/12/2013Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseAn International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver DiseasePolycystic Liver Disease (PLD):;Polycystic Kidney, Autosomal Dominant;Polycystic Liver DiseaseDrug: Ursodeoxycholic AcidRadboud UniversityAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);Biodonostia Health Research InstituteCompleted18 Years80 YearsBoth34Phase 2Netherlands;Spain
3EUCTR2013-003207-19-NL
(EUCTR)
29/11/201308/08/2013Trial to investigate the effect of ursodeoxycholic acid as a treatment of symptoms in polycystic liver disease: the CURSOR-trialAn international, multicenter, randomized controlled clinical trial assessing the efficacy of Ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic livers - The CURSOR trial Patients suffering from symptomatic polycystic liver disease (PLD) with underlying diagnosis of isolated polycystic liver disease (PCLD) or autosomal dominant kidney disease (ADPKD);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: URSOCHOL 300Radboud University Nijmegen Medical CenterNULLNot RecruitingFemale: yes
Male: yes
34Phase 4Spain;Netherlands